Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 PK, safety, and tolerability of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis (6–11 years)
2018-001695-38Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoints: Pharmacokinetics (Part B) and Safety and tolerability (Part B). Started Aug 2019; status: completed.
02
Drugs
elexacaftor + tezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-001695-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001695-38.